Olivia Cano-Garrido
Overview
Explore the profile of Olivia Cano-Garrido including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
365
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cano-Garrido O, Serna N, Unzueta U, Parlade E, Mangues R, Villaverde A, et al.
Biotechnol Adv
. 2022 Sep;
61:108032.
PMID: 36089254
Fundamental clinical areas such as drug delivery and regenerative medicine require biocompatible materials as mechanically stable scaffolds or as nanoscale drug carriers. Among the wide set of emerging biomaterials, polypeptides...
2.
Barguilla I, Unzueta U, Carratala J, Cano-Garrido O, Villaverde A, Hernandez A, et al.
Front Bioeng Biotechnol
. 2022 May;
10:842256.
PMID: 35573225
Bacterial inclusion bodies (IBs) are discrete macromolecular complexes that appear in recombinant prokaryotic cells under stress conditions. These structures are often discarded for biotechnological uses given the difficulty in recovering...
3.
Parlade E, Volta-Duran E, Cano-Garrido O, Sanchez J, Unzueta U, Lopez-Laguna H, et al.
Int J Mol Sci
. 2022 May;
23(9).
PMID: 35563346
Under the need for new functional and biocompatible materials for biomedical applications, protein engineering allows the design of assemblable polypeptides, which, as convenient building blocks of supramolecular complexes, can be...
4.
Seras-Franzoso J, Cano-Garrido O, Peternel S, Aris A, Garcia-Fruitos E
Methods Mol Biol
. 2022 Jan;
2406:401-416.
PMID: 35089571
Purification of inclusion bodies (IBs) is gaining importance due to the raising of novel applications for these submicron particulate protein clusters, with potential uses in the biomedical and biotechnological fields...
5.
Pares S, Cano-Garrido O, Bach A, Ferrer-Miralles N, Villaverde A, Garcia-Fruitos E, et al.
Animals (Basel)
. 2021 Dec;
11(12).
PMID: 34944191
The dry period is decisive for the milking performance of dairy cows. The promptness of mammary gland involution at dry-off affects not only the productivity in the next lactation, but...
6.
Aguado M, Saldana L, Perez Del Rio E, Guasch J, Parera M, Cordoba A, et al.
Polymers (Basel)
. 2021 Oct;
13(20).
PMID: 34685212
Fabricating polymeric scaffolds using cost-effective manufacturing processes is still challenging. Gas foaming techniques using supercritical carbon dioxide (scCO) have attracted attention for producing synthetic polymer matrices; however, the high-pressure requirements...
7.
Lopez-Laguna H, Sanchez J, Carratala J, Rojas-Pena M, Sanchez-Garcia L, Parlade E, et al.
ACS Sustain Chem Eng
. 2021 Oct;
9(36):12341-12354.
PMID: 34603855
We have developed a simple, robust, and fully transversal approach for the fabrication of functional multimeric nanoparticles with potential biomedical applications, validated here by a set of diverse and unrelated...
8.
Cano-Garrido O, Alamo P, Sanchez-Garcia L, Falgas A, Sanchez-Chardi A, Serna N, et al.
Cancers (Basel)
. 2021 Jul;
13(12).
PMID: 34208189
The accumulated molecular knowledge about human cancer enables the identification of multiple cell surface markers as highly specific therapeutic targets. A proper tumor targeting could significantly avoid drug exposure of...
9.
Alamo P, Cedano J, Conchillo-Sole O, Cano-Garrido O, Alba-Castellon L, Serna N, et al.
Acta Biomater
. 2021 Jun;
130:211-222.
PMID: 34116228
Green fluorescent protein (GFP) is a widely used scaffold for protein-based targeted nanomedicines because of its high biocompatibility, biological neutrality and outstanding structural stability. However, being immunogenicity a major concern...
10.
Volta-Duran E, Serna N, Sanchez-Garcia L, Avino A, Sanchez J, Lopez-Laguna H, et al.
Acta Biomater
. 2020 Nov;
119:312-322.
PMID: 33189955
The possibility to conjugate tumor-targeted cytotoxic nanoparticles and conventional antitumoral drugs in single pharmacological entities would open a wide spectrum of opportunities in nanomedical oncology. This principle has been explored...